Martina Mutone, MD
Urogynecology and Reconstructive Pelvic Surgery · Fishers, INNPI 1619981545
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.0%), food and beverage and gifts — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 54.0% of the total. Reporting peaked in 2019 at $4,282 and has fallen 86.1% since, to $594 in 2025.
Across 131 payments — averaging $56.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Axonics, Inc.$931
- AbbVie$683
- Caldera Medical, Inc$217
- Medtronic$204
- Sumitomo Pharma America, Inc.$172
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$4,00054%
- Food & beverage$3,37346%
- Gifts$381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 1 | $4,000 |
| Axonics, Inc. | 19 | $931 |
| AbbVie(2 entities) | 34 | $683 |
| Caldera Medical, Inc | 2 | $217 |
| Medtronic(2 entities) | 9 | $204 |
| Sumitomo Pharma America, Inc. | 7 | $172 |
| Johnson & Johnson | 4 | $126 |
| Bayer | 8 | $120 |
| Novartis | 4 | $103 |
| Blue Earth Diagnostics | 3 | $74 |
| Laborie Medical Technologies Corp. | 3 | $68 |
| Astellas Pharma US Inc | 4 | $60 |
| Coloplast | 3 | $57 |
| Dendreon Pharmaceuticals LLC | 2 | $52 |
| Tolmar, Inc. | 3 | $51 |
| Accord Healthcare, Inc. | 3 | $50 |
| Rochester Medical Corporation | 1 | $50 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $49 |
| Abbott | 1 | $45 |
| Urovant Sciences Inc | 2 | $37 |
| AstraZeneca(2 entities) | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| EDAP Technomed Inc | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Olympus America Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 2 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Stryker | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
| Asensus Surgical, Inc. | 1 | $13 |
| Mission Pharmacal Company | 1 | $11 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,000
- Axonics$335
- INTERSTIM$110
- Bulkamid$108
How this compares
$7,411 in reported general payments places this provider in the 65th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Indiana.
See all urogynecology and reconstructive pelvic surgery providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 40 | $42,422 |
| MyrbetriqMirabegron | 59 | $37,848 |
| Estradiol | 279 | $19,589 |
| PremarinEstrogens, Conjugated | 21 | $11,842 |
| YuvafemEstradiol | 27 | $5,770 |
| Trimethoprim | 26 | $1,300 |
| Cephalexin | 179 | $430 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 34 | $317 |
| Oxycodone Hcl | 153 | $310 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $293 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 75 | $136 |
| Clindamycin Hcl | 39 | $115 |
| Ciprofloxacin Hcl | 12 | $46 |
| Tramadol Hcl | 23 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $172 | $42,42240 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $37,84859 claims |
| PfizerPremarin | $11 | $11,84221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 urogynecology and reconstructive pelvic surgery providers in Indiana.
Other urogynecology and reconstructive pelvic surgery in Fishers
- Cindy BasinskiNewburgh$132K
- Kathryn CopelandCarmel$26K
- Jeffrey BlakeNoblesville$15K
- Ted RothSouth Bend$14K
- Krystine GulbrandDanville$13K
- Hussein WardaGreenwood$10K
- Amanda LaporteIndianapolis$9K
- Scott BoydFort Wayne$7K
- Sara Diaz ValentinRichmond$7K
- Preston EdgeNewburgh$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.